$23.48
0.20 (+0.86%)
Myriad Genetics, Inc. (NASDAQ:MYGN)
CAPS Rating:
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.